JP2013510882A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510882A5
JP2013510882A5 JP2012539057A JP2012539057A JP2013510882A5 JP 2013510882 A5 JP2013510882 A5 JP 2013510882A5 JP 2012539057 A JP2012539057 A JP 2012539057A JP 2012539057 A JP2012539057 A JP 2012539057A JP 2013510882 A5 JP2013510882 A5 JP 2013510882A5
Authority
JP
Japan
Prior art keywords
group
pgp
immunogenic composition
protecting
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510882A (ja
JP6091214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056742 external-priority patent/WO2011060379A2/en
Publication of JP2013510882A publication Critical patent/JP2013510882A/ja
Publication of JP2013510882A5 publication Critical patent/JP2013510882A5/ja
Application granted granted Critical
Publication of JP6091214B2 publication Critical patent/JP6091214B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539057A 2009-11-16 2010-11-15 ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン Expired - Fee Related JP6091214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26157209P 2009-11-16 2009-11-16
US61/261,572 2009-11-16
PCT/US2010/056742 WO2011060379A2 (en) 2009-11-16 2010-11-15 (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine

Publications (3)

Publication Number Publication Date
JP2013510882A JP2013510882A (ja) 2013-03-28
JP2013510882A5 true JP2013510882A5 (enExample) 2013-12-05
JP6091214B2 JP6091214B2 (ja) 2017-03-08

Family

ID=43992459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539057A Expired - Fee Related JP6091214B2 (ja) 2009-11-16 2010-11-15 ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン

Country Status (6)

Country Link
US (1) US20130052204A1 (enExample)
EP (1) EP2501403A4 (enExample)
JP (1) JP6091214B2 (enExample)
AU (2) AU2010320031B2 (enExample)
CA (1) CA2781049A1 (enExample)
WO (1) WO2011060379A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120140B1 (en) * 2014-03-21 2018-10-31 Biotage AB Method and apparatus for the equilibration of a packed chromatography column
US10781175B2 (en) 2016-07-15 2020-09-22 Am Chemicals Llc Solid supports and phosphoramidite building blocks for oligonucleotide conjugates
WO2025166099A1 (en) * 2024-02-02 2025-08-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Fire-retardant wood and wood composites, and compositions useful for making same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
GB9811347D0 (en) * 1998-05-28 1998-07-22 Oxoid Ltd Improvements in or relating diagnosis and treatment of bacterial infections
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
AU2004299501B2 (en) * 2003-12-17 2010-12-23 Wyeth Llc Immunogenic peptide carrier conjugates and methods of producing same
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection

Similar Documents

Publication Publication Date Title
JP5745221B2 (ja) タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法
JP5491853B2 (ja) 免疫原性組成物
JP6335326B2 (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
RU2378008C2 (ru) Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
JP6950099B2 (ja) 多価肺炎球菌多糖体−タンパク質複合体組成物
Lockner et al. Flagellin as carrier and adjuvant in cocaine vaccine development
JP2010518082A5 (enExample)
CN105188744A (zh) 基于纳米颗粒的组合物
JP2017014217A (ja) 合成ナノキャリア混合ワクチン
WO2005037320A2 (en) Process for preparing polysaccharide-protein conjugate vaccines
ES2728653T3 (es) Composiciones vacunales con una matriz proteica que incluye policationes
Crothers et al. Recent advances in enterotoxin vaccine adjuvants
Yu et al. Quaternized chitosan nanoparticles in vaccine applications
JP2013504588A (ja) 免疫原性の高いタンパク質マトリックスワクチン
JP2004508065A5 (enExample)
Simerska et al. Oral vaccine delivery-new strategies and technologies
JP2013510882A5 (enExample)
Lin et al. Polyphosphazene: A new adjuvant platform for cocaine vaccine development
US12390485B2 (en) Compounds and methods for suppressing an immune response to substances containing polyethylene glycol
WO2021244996A1 (en) Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
US20230063876A1 (en) Virus-Like Particle Vaccines for Opioid Drugs
Anish et al. Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity
JP6091214B2 (ja) ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン
KR20220144830A (ko) 펩티드-멜라닌 결합 최적화
CN104189901A (zh) 一种肺炎球菌缀合疫苗及其制备方法